Company press release


Research-Collaboration-Agreement between the Charité Berlin and Proteo Biotech AG

Kiel, July 26, 2004: The effect that Elafin as a protease inhibitor in the medical field of organ transplantations has will be thoroughly tested and analysed.

After signing the research agreement Proteo Biotech AG has provided the clinic of general-, visceral- and transplantation surgery of the Charité in Berlin with the unique agent Elafin. It is the objective to perform various tests in the coming months to develop and deduce new indications for the protease inhibitor Elafin. It is likely and probable that Elafin, as a highly effective inhibitor of human leukocyte elastase, also can be used for a variety of other applications which have not been tested yet.é-berlin-and-proteo-biotech-ag/ – printed on 2020-09-23 18:43:51